# Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

> **NCT01353027** · PHASE1 · COMPLETED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Ebola Hemorrhagic Fever

## Interventions

- **DRUG:** Placebo
- **DRUG:** AVI-6002

## Key facts

- **NCT ID:** NCT01353027
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353027, "Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01353027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*